Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.

摘要: Abstract In this phase II study, activity and safety of neoadjuvant regional hyperthermia (RHT) combined with chemotherapy was investigated in 59 patients primary advanced or recurrent high-risk soft-tissue sarcoma (STS). Patients received four EIA cycles consisting etoposide, ifosfamide doxorubicin RHT followed by surgical resection adjuvant treatment. The overall objective response (OR) rate 17%, one complete (2%) eight partial (15%) responses. addition, 13 minor reponses (25%) were seen. At time surgery, necrosis (pCR) occurred 6 >75% (favourable histological (FHR)) 12 patients. the completion protocol treatment, 36 rendered disease-free which significantly associated initial radiographic and/or pathological tumour ( P =0.004). Treatment-related toxicity acceptable overall. a medium follow-up 82 months, local treatment failure 33 patients, median survival (OS) 52 5-year 49% (95% confidence interval (CI): 36–61%). OS did not differ for extremity versus non-extremity STS =0.21) better responding to